Development of a novel lung cancer biomarker using CKAP4 Sandwich-ELISA

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17746
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55040:Respiratory surgery-related
• Research Institution: Osaka University
• Principal Investigator: Nagoya Akihiro 大阪大学, 医学部附属病院, 医員 (90860297)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: CKAP4 / exosomes / lung cancer / biomarker

Outline of Final Research Achievements

Serum CKAP4 levels were measured in 92 lung cancer patients and the same number of age- and sex-matched healthy controls by sandwich ELISA using anti-CKAP4 antibody.
The finding was that the serum CKAP4 positivity (> 0.1 ng/mL) was significantly higher in lung cancer patients (19.6%) than in healthy controls (6.5%). In addition, anti-CKAP4 antibody inhibited the growth of human lung cancer cell lines by inhibiting the phosphorylation of AKT both in vitro and in vivo. These effects were enhanced against human lung cancer cells with EGFR mutations when combined with an existing EGFR inhibitor (osimertinib).

Free Research Field

肺がん

Academic Significance and Societal Importance of the Research Achievements

肺癌患者では健常人に比べて有意に血清CKAP4濃度が高いことから、血清CKAP4濃度をサンドイッチELISA法で測定することで、肺癌診断が可能となる可能性が示唆された。同時に抗CKAP4は単剤および既存の抗癌剤との併用で、ヒト肺癌細胞の増殖を抑制した。以上の結果から、肺癌においてはCKAP4が新規診断マーカーと共に治療標的分子となり得ることが示唆された。